Investor Presentaiton
2Q23 Business Results
Key Products
Appendix
Revenue: Increased both QoQ and YoY due to stable prescription of highly profitable products such as Remsima®, RemsimaⓇSC and YuflymaⓇ
Operating Profit: Cost increased by expansion of the direct sales and sales operations resulted in lower OP although the revenue was increased by the sales of high-margin products
Net Profit: Inventory of subsidiary in Hungary purchased from the headquarter resulted in unrealized gain which increased the income tax rate, and NP decreased in a consequence
2Q23 Business Results
(KRW bn)
'22.2Q
'23.1Q
'23.2Q
% YoY
%QoQ
Revenue
519.0
503.6
525.8
1.3%
4.4%
Gross Profit
140.9
153.2
150.9
7.1%
-1.5%
(%)
27.1%
30.4%
28.7%
1.6%p
-1.7%p
SG&A
66.8
102.2
116.8
74.9%
14.3%
(%)
12.9%
20.3%
22.2%
9.3%p
1.9%p
Personnel expenses
13.7
18.1
19.7
43.8%
8.8%
Research expenses
0.8
4.6
9.4
1,075.0%
104.3%
Advertising expenses
6.6
10.2
15.5
134.8%
52.0%
Commissions
24.3
30.1
37.8
55.6%
25.6%
Transportation expenses
7.8
13.9
11.3
44.9%
-18.7%
Operating Profit
74.1
51.0
34.1
-54.0%
-33.1%
(%)
14.3%
10.1%
6.5%
-7.8%p
-3.6%p
EBIT
95.2
120.1
32.1
-66.3%
-73.3%
Net Profit
39.1
54.1
17.4
-55.5%
-67.8%
Investor Relations 2023 3View entire presentation